PNBK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PNBK is not a good buy right now. The technical setup is bearish (downtrend signals across moving averages with negative MACD), there are no Intellectia buy signals to override the setup, and the latest quarter shows worsening profitability (net loss and EPS collapse). With no recent news catalysts and no notable institutional/insider momentum, the risk/reward does not favor an impatient buyer at the current price.
Trend/price action: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), implying the broader and intermediate trend is down and the stock is not reclaiming strength. Momentum: MACD histogram is negative (-0.0149) and still below zero, though contracting—this suggests downside momentum is easing but not reversed. RSI: RSI_6 at 44.864 is neutral-to-weak (not oversold), so there is no strong mean-reversion buy signal. Levels: Pivot 1.578 is above the current price 1.55, so price is trading below the pivot (bearish). Nearby support is S1 1.517 then S2 1.479; resistance is R1 1.639 then R2 1.677. Pattern-based odds: Similar-pattern projection shows only modest upside over week/month (+0.31% / +0.62%) and slight weakness next day (-0.22%), not a compelling edge for an impatient entry.
Intellectia Proprietary Trading Signals
Revenue growth in 2025/Q3 (+6.09% YoY) indicates some top-line stability.
MACD negative momentum is contracting, which can sometimes precede stabilization if price reclaims key levels (e.g., pivot 1.578).
Clear bearish trend: SMA_200 > SMA_20 > SMA_5 and price below pivot level.
Profitability deterioration: 2025/Q3 net income fell to -2.657M (down ~90% YoY) and EPS dropped to -0.03 (down ~99.56% YoY).
No news in the past week: lack of event-driven catalysts to quickly change sentiment.
No proprietary buy signals (AI Stock Picker / SwingMax) to justify an aggressive entry.
Trading trends: Hedge funds neutral and insiders neutral—no supportive accumulation signal.
Latest quarter: 2025/Q3. Revenue rose to $5.68M (+6.09% YoY), but profitability worsened materially with net income at -$2.657M (down ~90.14% YoY) and EPS at -0.03 (down ~99.56% YoY). Overall: top-line growth but sharply deteriorating earnings trend, which is a negative setup for near-term buying.
No analyst rating or price target change data was provided, so there is no clear Wall Street consensus signal to support a buy. Pros would be modest revenue growth; cons are the steep deterioration in earnings and the current bearish technical trend.
